Ratings
0
Nobody has rated this yet. Be the first!
Works
2
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
